文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

Tafamidis在八十岁以上野生型转甲状腺素蛋白心肌病患者中的国际队列研究

Tafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study.
PubMed 文献 · Eur Heart J · 2025-01-01

这项国际多中心队列研究纳入710例野生型转甲状腺素蛋白心肌病患者,评估Tafamidis在八十岁以上患者中的疗效。倾向性评分匹配后,Tafamidis治疗与较低死亡率相关(HR=0.53,95%CI 0.34-0.84,P=.007),但八十岁以上患者死亡率仍较高,90岁以上或NAC分期≥3者预后更差。

要点

  • Tafamidis治疗与八十岁以上野生型ATTR-CM患者较低死亡率相关,年龄不影响疗效。
  • 九十岁以上启动治疗或NAC分期≥3的八十岁以上患者生存仍较差。
  • 八十岁以上患者Tafamidis停药率与非八十岁以上患者相似。

核心结论

  • 真实世界中Tafamidis治疗改善生存,年龄不影响治疗疗效,但八十岁以上患者死亡率仍较高。

研究设计与样本

  • 国际多中心队列研究,纳入710例连续野生型转甲状腺素蛋白心肌病患者,平均随访2.2±1.8年,终点为全因死亡。

主要发现

  • 队列中58.5%(415/710)为八十岁以上患者(85±4岁,74.2%男性)。
  • Tafamidis上市前,八十岁以上患者1年死亡16%、5年死亡71%,非八十岁以上患者分别为8%和47%(P<.001)。
  • Tafamidis上市后,七十岁以上患者70.1%(253/361)启动治疗,非八十岁以上患者83.7%(231/276)启动治疗(P<.001)。
  • Tafamidis停药率:八十岁以上10.3%,非八十岁以上7.4%(P=.260)。
  • 倾向性评分匹配平均394例后,Tafamidis治疗与较低死亡率相关(HR=0.53,95%CI 0.34-0.84,P=.007)。

关键数值与推荐

  • 匹配后八十岁以上亚组:HR=0.57,95%CI 0.33-1.01,P=.053。
  • 诊断年龄(P=.217)或治疗启动年龄(P=.154)与Tafamidis死亡率获益无交互作用。
  • 九十岁以上启动治疗者HR=3.3,95%CI 1.10-9.53,P=.033;NAC分期≥3者HR=2.4,95%CI 0.87-6.46,P=.090。

临床怎么用

  • 八十岁以上野生型ATTR-CM患者可考虑Tafamidis治疗,年龄本身不应限制治疗决策。
  • 九十岁以上或NAC分期≥3的八十岁以上患者预后仍较差,需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: In real-world, wild-type transthyretin cardiomyopathy is increasingly diagnosed in patients ≥ 80 years old (octogenarians), although being underrepresented in randomized clinical trials. Specific data on natural course and outcome under tafamidis treatment in octogenarians are therefore scarce. The impact of tafamidis treatment on mortality in real-world wild-type transthyretin cardiomyopathy octogenarians was studied. METHODS: An international, multicentre cohort study of 710 consecutive wild-type transthyretin cardiomyopathy patients with mean follow-up of 2.2 ± 1.8 years for all-cause mortality endpoint was performed. RESULTS: The cohort consisted of 58.5% (415/710) octogenarians (85 ± 4 years, 74.2% male). Before tafamidis availability, natural course in octogenarians (148/257) vs. non-octogenarians (109/257) was poor, with 16% 1-year and 71% 5-year mortality vs. 8% and 47%, respectively (P < .001). Since tafamidis availability, 70.1% (253/361) octogenarians were initiated on tafamidis vs. 83.7% (231/276) non-octogenarians (P < .001). Tafamidis discontinuation was similar (octogenarians 10.3% and non-octogenarians 7.4%; P = .260). Overall tafamidis treated vs. untreated octogenarians had better unadjusted survival (P < .001), with 5% 1-year and 24% 3-year mortality. Tafamidis treatment associated with lower mortality after propensity score matching on baseline variables, including age, National Amyloidosis Centre stage, and New York Heart Association class in on average 394 subjects [hazard ratio (HR) = 0.53, 95% confidence interval (CI) 0.34-0.84, P = .007], also in octogenarians (HR = 0.57, 95% CI 0.33-1.01, P = .053). Neither age at diagnosis (P = .217) nor at treatment initiation (P = .154) interacted with tafamidis mortality benefit. Octogenarians had poorer survival despite tafamidis, when initiated at ≥90 years (HR = 3.3, 95% CI 1.10-9.53, P = .033) and National Amyloidosis Centre Stage ≥3 (HR = 2.4, 95% CI 0.87-6.46, P = .090). CONCLUSIONS: Real-world tafamidis treatment improves survival without age affecting treatment efficacy, although mortality remains considerable in octogenarians.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Debonnaire P, Dujardin K, Verheyen N, et al. Tafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study. Eur Heart J. 2025. PMID: 40036202. doi:10.1093/eurheartj/ehae923

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。